Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy

Yehoda M. Martei, MD, MSCE1,2; Mohan Narasimhamurthy, MD3; Dipho I. Setlhako, MD4; Gezahen Ayane, MBBS5; Tlotlo Ralefala, MD4; Sebathu Chiya, MD5; Robert Gross, MD6; Lawrence N. Shulman, MD1; Surbhi Grover, MD2,7; and Angela DeMichele, MD1

PURPOSE Patients who are HIV-positive and have breast cancer have worse overall survival (OS) compared with patients who are HIV-negative. Pathologic complete response (pCR) and relative dose intensity (RDI) of chemotherapy are associated with survival. We assessed whether pCR and RDI rates were lower for patients who are HIV-positive and received neoadjuvant chemotherapy (NACT).

METHODS This was a prospective cohort analysis of patients initiating NACT in Botswana (February 2017 to September 2019). Primary outcomes were pCR and RDI; secondary outcomes were OS and toxicity. HIV status and zidovudine (ZDV) treatment were stratification factors. Multivariable analysis was used to control for confounding.

RESULTS In total, 26 of 110 enrolled individuals were HIV-positive. In univariable analysis, HIV-positive (odds ratio [OR] = 0.2; \( P = .048 \)) and RDI < 0.85 (OR = 0.30; \( P = .025 \)) were associated with pCR. In multivariable analysis, the magnitude of association decreased for HIV-positive (OR = 0.28; \( P = .11 \)), but RDI < 0.85 remained independently associated with pCR (OR = 0.32; \( P = .035 \)). Patients who are HIV-positive had significantly lower mean RDI, and those on ZDV had significantly lower RDI. Ninety-one (83%) were stage III with 2-year OS significantly worse for patients who are HIV-positive (58% v 74%). Hazard ratio for all-cause mortality was 2.68 (95% CI, 1.17 to 6.13; \( P = .028 \)) in patients who are HIV-positive compared with patients who are HIV-negative. Toxicity rates were similar despite patients who are HIV-positive receiving significantly lower dose intensity chemotherapy.

CONCLUSION Patients who are HIV-positive and have breast cancer in Botswana have lower pCR rates and also receive lower dose intensity therapy, which may contribute to worse OS. Patients who are HIV-positive on ZDV-containing regimens received even lower dose intensity of NACT. Administering optimal dose intensity in patients who are HIV-positive remains a challenge, and targeted interventions that address modifiable risk factors are needed to improve therapy delivery and outcomes.
is a strong predictor of event-free survival (EFS) within specific molecular subtypes. Relative dose intensity (RDI) is a composite measure that includes actual cumulative dose of chemotherapy received and duration of treatment received, expressed as a proportion of the intended standard dose and duration of therapy. RDI < 0.85 has been associated with worse survival in patients with nonmetastatic breast cancer. We hypothesized that patients who are HIV-positive in Botswana might receive lower RDI that may have an adverse impact on pCR rates and subsequent survival. Therefore, our aim was to assess whether pCR rates were lower for patients who are HIV-positive and received NACT compared with patients who are HIV-negative and who are diagnosed with breast cancer.

## METHODS

### Study Design and Participants

This was a prospective cohort study of patients who are HIV-positive or HIV-negative with newly diagnosed breast cancer, age ≥ 18 years, and with stage I-III disease who initiated NACT at Princess Marina Hospital, the largest cancer care referral center in Botswana. Patients who were pregnant, had previously undergone excisional biopsy, received prior chemotherapy, or unable to consent were excluded. Informed consent was obtained before enrollment. This study was approved by the Institutional Review Boards at the University of Pennsylvania, the Botswana Human Research Development Committee, Ministry of Health, and Princess Marina Hospital.

### Treatment

Guidelines for breast cancer NACT treatment in Botswana is aligned with the National Comprehensive Cancer Network harmonized guidelines for enhanced resource countries, which consists of doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² once a day, every 21 days for four cycles, followed by paclitaxel 175 mg/m² once a day every 21 days, for four cycles (doxorubicin plus cyclophosphamide, followed by paclitaxel [AC-T]); plus trastuzumab 6 mg/kg once a day every 21 days for patients with human epidermal growth factor receptor 2 (HER2)–positive tumors (AC-TH). Primary prophylaxis with granulocyte colony-stimulating factor is not administered in patients receiving AC-T. If operable, patients are recommended to undergo modified radical mastectomy (approximately 4-6 weeks after the last cycle of chemotherapy) with pathology evaluation of response of surgical specimen. Breast conservation surgery is rarely offered because of lack of surgical expertise and image-guided resources. All pathology assessments were performed using standardized criteria at the Botswana National Health Laboratory. Patients with hormone receptor-positive disease and HER2-positive disease were prescribed endocrine therapy and trastuzumab, respectively.

## CONTEXT

### Key Objective

To evaluate survival outcomes in patients living with HIV and patients who are HIV-negative and have breast cancer in Botswana and furthermore to assess whether patients who are HIV-positive receive lower relative dose intensity (RDI) of neoadjuvant chemotherapy and have lower pathologic complete response rates.

### Knowledge Generated

Patients who are HIV-positive received significantly lower RDI of chemotherapy, with lowest RDI in patients on zidovudine-based antiretroviral regimens. Furthermore, patients who are HIV-positive had lower pathologic complete response rates. We observed differences in our prospective cohort may partly account for survival disparities between patients who are HIV-positive and HIV-negative and who are diagnosed with breast cancer.

### Relevance

Administering optimal dose intensity chemotherapy in patients with HIV and who have breast cancer remains a challenge and adversely affects survival. Care integration with HIV specialists and pharmacists should be considered to address modifiable risk factors.

© 2022 by American Society of Clinical Oncology
Primary Outcome and Exposure

Our primary outcomes were RDI and pCR. Since RDI < 0.85 for adjuvant chemotherapy regimens has been associated with inferior disease-free survival and OS in patients with breast cancer, we used this as a cutoff for suboptimal therapy receipt. We also assessed RDI as a continuous variable and compared means of the RDI stratified by HIV status and treatment. pCR was defined as no residual invasive cancer in the breast and lymph nodes, with noninvasive residual disease in breast allowed, and was analyzed overall for the group and by receptor status—classified as triple-negative, HER2-positive, or hormone receptor-positive/HER2-negative. Secondary outcomes were toxicity and OS by HIV status. OS was defined as time from initiation of treatment until death from any cause.

Statistical Analysis

Chi-squared ($\chi^2$) or Fisher’s exact tests (when expected cell size was < 5) were used to compare proportions of categorical patient baseline, tumor, and treatment characteristics in patients who are HIV-positive and HIV-negative. Student’s $t$-tests were used to compare means of normally distributed continuous variables, and Wilcoxon rank-sum tests were used to compare medians of continuous variables with nonparametric distributions. The OS analyses were performed using the Kaplan-Meier estimator and limited to stage III patients who were the majority of patients, given the wide variation in breast cancer survival by stage. Comparisons of OS between patients who were HIV-positive and HIV-negative were analyzed using log-rank tests and crude hazard ratios (HRs) and corresponding 95% CIs, computed using Cox proportional hazards regression. Within the population who are HIV-positive, two further subcohorts were created on the basis of whether the ART regimen was zidovudine (ZDV)-containing versus non–ZDV-containing, since ZDV is known to cause myelosuppression. RDI analyses were repeated by using the ZDV regimen. Grade ≥ 3 toxicity rates were compared by HIV status and ZDV regimen. Multivariable linear and logistic regressions were used to control for potential confounding variables for RDI and pCR, respectively. Covariates significantly associated with exposure and outcome with $P < .2$ in the univariable or bivariable analyses were included in the multivariable model. For pCR analysis, hormone receptor status was forced in the model given the known association with pCR in the literature. Analyses were carried out in STATA version 16 (StataCorp, College Station, TX). $P$ values for pCR analyses were a priori one-sided given the aim to test only if rates were lower for HIV-positive than HIV-negative; all other $P$ values were two-sided.

RESULTS

One hundred eleven eligible patients with breast cancer were prospectively enrolled from February 2017 to September 2019. One patient was excluded after enrollment because she had an excisional biopsy, resulting in 110 patients, including 26 (24%) with HIV in this analysis (Fig 1). Patients who are HIV-positive were significantly younger at diagnosis, less likely to be overweight or obese, and more likely to have hormone receptor-positive disease (Table 1). All but one patient who is HIV-positive were significantly younger at diagnosis, less likely to be overweight or obese, and more likely to have hormone receptor-positive disease. Patients who are HIV-positive were significantly younger at diagnosis, less likely to be overweight or obese, and more likely to have hormone receptor-positive disease (Table 1). All but one patient who is HIV-positive was receiving ART (Table 1). Nine patients who are HIV-positive (35%) were on ZDV-containing treatment regimens (Table 1).
**TABLE 1.** Baseline Demographic and Clinical Characteristics of Patients Who Are HIV-Positive and Have Breast Cancer and Patients Who Are HIV-Negative and Have Breast Cancer Who Initiated Neoadjuvant Chemotherapy at Princess Marina Hospital in Gaborone, Botswana

| Characteristic | HIV-Negative (N = 84) | HIV-Positive (N = 26) | Total (N = 110) | P  |
|---------------|-----------------------|-----------------------|----------------|----|
| Mean age (95% CI), years | 54.6 (51.6 to 57.7) | 46.1 (41.2 to 50.9) | 52.6 (50.0 to 55.2) | .0060 |
| HR status, No. (%) | | | | .0330 |
| Positive | 45 (53.6) | 18 (69.2) | 63 (57.3) | |
| Negative | 39 (46.4) | 5 (19.2) | 44 (40.0) | |
| Missing | 0 (0.0) | 3 (11.5) | 3 (2.7) | |
| HER2 status, No. (%) | | | | .6040 |
| Positive | 25 (29.8) | 5 (19.2) | 30 (27.3) | |
| Negative | 57 (67.9) | 16 (61.5) | 73 (66.4) | |
| Missing | 2 (2.4) | 5 (19.2) | 7 (6.4) | |
| Molecular subtype, No. (%) | | | | .2770 |
| HR-negative, HER2-negative | 25 (29.8) | 3 (11.5) | 28 (25.5) | |
| HR-negative, HER2-positive | 13 (15.5) | 2 (7.7) | 15 (13.6) | |
| HR-positive, HER2-negative | 32 (38.1) | 13 (50.0) | 45 (40.9) | |
| HR-positive, HER2-positive | 12 (14.3) | 3 (11.5) | 15 (13.6) | |
| Missing | 2 (2.4) | 5 (19.2) | 7 (6.4) | |
| Clinical staging at presentation, No. (%) | | | | .3360 |
| Stage I | 0 (0.0) | 1 (3.8) | 1 (0.9) | |
| Stage II | 14 (16.7) | 4 (15.4) | 18 (16.4) | |
| Stage III | 70 (83.3) | 21 (80.8) | 91 (82.7) | |
| Intended neoadjuvant regimens, No. (%) | | | | .5710 |
| AC-T(H) | 63 (75.0) | 23 (88.5) | 86 (78.2) | |
| CMF | 3 (3.6) | 0 (0.0) | 3 (2.7) | |
| TC | 1 (1.2) | 0 (0.0) | 1 (0.9) | |
| TCH | 13 (15.5) | 2 (7.7) | 15 (13.6) | |
| Nonstandard regimen | 4 (4.8) | 1 (3.8) | 5 (4.5) | |
| Receipt of anti-HER2 therapy, No. (%) | | | | 1.0000 |
| Yes | 21 (84) | 4 (80) | 25 (83.3) | |
| No | 4 (16) | 1 (20) | 5 (16.7) | |
| BMI, No. (%) | | | | < .0010 |
| Normal weight | 17 (20.2) | 11 (42.3) | 28 (25.5) | |
| Underweight | 1 (1.2) | 3 (11.5) | 4 (3.6) | |
| Overweight | 18 (21.4) | 8 (30.8) | 26 (23.6) | |
| Obese | 44 (52.3) | 3 (11.5) | 47 (42.7) | |
| Missing | 4 (4.8) | 1 (3.8) | 5 (4.5) | |
| Baseline laboratory data | | | | |
| WBC, median (IQR), 10⁹/L | 6.7 (5.3 to 8.3) | 5 (4.5 to 6.7) | 6.5 (5 to 8) | .0020 |
| ANC, median (IQR), 10⁹/L | 3.7 (2.8 to 4.9) | 2.6 (2 to 3.5) | 3.3 (2.5 to 4.8) | .0028 |
| Hemoglobin, median (IQR), g/dL | 12.95 (12.1 to 13.8) | 12.8 (12.1 to 13.9) | 12.9 (12.1 to 13.8) | .8091 |
| Platelet count, mean (SD), 10⁹/L | 314 (81) | 322 (95) | 316 (84) | .6900 |
| HIV characteristics only, No. (%) | | | | |
| ART | | | | |
| 3TC/ABC/SQV | 1 (3.8) | | | |
| Atripla | 10 (38.5) | | | |

(Continued on following page)
Pathologic Complete Response

Of the patients who underwent surgery and had adequate surgical pathology data (n = 86), the pCR rate was significantly lower among patients who are HIV-positive compared with patients who are HIV-negative (5% [1/20] vs 21% [14/52]; odds ratio [OR] = 0.20; one-sided \( P = .048 \)). As expected, pCR rates by receptor status were highest overall in HER2-positive disease, followed by triple-negative disease and hormone receptor-positive/HER2-negative disease (Table 2). In the univariable analysis, RDI, \( 0.85 \) was associated with pCR (OR = 0.3; one-sided \( P = .03 \)), but age at diagnosis, hormone receptor status, and BMI were not associated with pCR with \( P, .2 \) threshold. In the multivariable analysis, including RDI and hormone receptor status forced into the model, HIV-positive (OR = 0.28; one-sided \( P = .11 \)) was not significantly associated with pCR, but RDI \( < 0.85 \) (OR = 0.32; one-sided \( P = 0.035 \)) was significantly associated with pCR. In the adjusted model, hormone receptor-positive status was associated with a lower likelihood of pCR, although the association was not significant in our cohort (OR=0.79; one-sided \( P = 0.31 \)).

Treatment Adequacy

Patients who are HIV-positive received a significantly lower mean RDI of NACT compared with patients who are HIV-negative (0.70 [95% CI, 0.61 to 0.792] vs 0.805 [95% CI, 0.761 to 0.849], \( P = .028 \); Table 2). Approximately half of patients who are HIV-negative (40 of 84) received neoadjuvant treatment with RDI \( \geq 0.85 \) compared with less than one-third (7 of 26) in the HIV-positive group (Table 2). Among patients who are HIV-positive, those taking ZDV-containing regimens received a lower mean RDI of 0.58 (95% CI, 0.38 to 0.77) compared with RDI = 0.77 (95% CI, 0.68 to 0.86) in patients taking non-ZDV-containing regimen (\( P = .0325 \)). Additionally, 78% (7 of 9) of patients on ZDV-containing regimen had RDI \( < 0.85 \) compared with 67% (10 of 15) of patients on non-ZDV-containing regimen (\( P = .669 \)).

In the simple linear regression model, HIV status (\( \beta = -0.11, P = .028 \)) significantly predicted RDI. Being overweight was associated with RDI (\( \beta = -0.14, P = .193 \)) and was included in the multiple linear regression model. In the adjusted model, HIV remained significantly associated with RDI (\( \beta = -0.12, P = .015 \)).

Treatment Patterns and Toxicity

Despite lower RDI in patients who are HIV-positive, rates of grade \( \geq 3 \) toxicity were similar in both groups, most commonly because of neutropenia or febrile neutropenia. The summary of other grade \( \geq 3 \) toxicity assessed by Common Terminology Criteria for Adverse Events criteria is provided in Table 2. We found a higher proportion of early discontinuation of systemic chemotherapy in the HIV-positive group compared with the HIV-negative group (35% [9/26] vs 23% [19/84], \( P = .20 \)); however, this difference was not statistically significant, and overall,
treatment discontinuation was high in both cohorts (Table 2). A detailed summary of chemotherapy administration data showed that the proportion of cycles with dose reductions in the first cycle was 14% (12 of 84) for the HIV-negative group compared with 24% (6 of 26) for the HIV-positive group ($P = .359$): 25% (4 of 16) for the non-ZDV group and 22% (2 of 9) for the ZDV group ($P = 1.00$). The proportion of patients with any dose reduction during treatment was 21% (18 of 84) for the HIV-negative group, compared with 32% (8 of 26) for the HIV-positive group.
(P = .184); 31% (5 of 16) for the non-ZDV group and 33% (3 of 9) for the ZDV group (P = .626). The mean duration of a cycle for patients who are HIV-negative was 27 days (95% CI, 26 to 29; median 25 days) and it was 31 days for those who are HIV-positive (95% CI, 27 to 35; median 28 days; \( P = .087 \)); 28 days for the non-ZDV group (95% CI, 24 to 32; median 27) and 35 days for the ZDV group (95% CI, 25 to 45; median 31 days; \( P = .091 \)).

**Survival Outcomes**

After a median follow-up of approximately 20 months, the estimated 2-year OS for stage III patients was significantly lower in patients who are HIV-positive and have breast cancer compared with patients who are HIV-negative and have breast cancer (58% vs 74%, respectively; Fig 2), with an unadjusted HR for death from any cause of 2.7 (95% CI, 1.2 to 6.1; \( P = .028 \)) for HIV-positive compared with HIV-negative. A similar trend of worse OS in the patient group who are HIV-positive and have breast cancer was observed for the combined cohort and subset of patients with hormone receptor-positive/HER2-negative disease only.

At the time of this analysis, 13 of 18 (72%) patients who are HIV-positive were on endocrine therapy compared with 73% (33 of 45) of patients who are HIV-negative; 1 of 45 (2%) in the HIV-negative group declined endocrine therapy and 1 of 45 (2%) was lost to follow-up. The remaining patients were deceased.

**DISCUSSION**

Although there is robust literature on survival outcomes in patients who are HIV-positive and have breast cancer, this prospective cohort analysis provides novel evidence showing that patients who are HIV-positive in Botswana received less dose-intense NACT and also have lower pCR rates. These lower pCR rates would be expected to lead to reduced EFS and OS, and we report lower OS for patients who are HIV-positive compared with patients who are HIV-negative.

This prospective study has several limitations. Because of the small sample size, this study was not powered to detect significant differences in subgroup analyses; therefore, clinically meaningful differences may not be statistically significant. An important limitation is that we could not assess the relationship between RDI and pCR rates within breast cancer subtypes. Patients with hormone receptor-positive disease have lower pCR rates than other subtypes, and we could not assess the attribution of low RDI on that rate specifically. Additionally, approximately 19% (5 of 26) of patients who are HIV-positive were missing receptor status for HER2 compared with 2.4% (2 of 84) in the HIV-negative group. The differential level of missingness of HER2 data has the potential to bias our results away from the null if there were more patients with HER2 disease who did not receive targeted anti-HER2 therapy, which would have improved response. However, within patients with known HER2-positive status, pCR rates were lower for HIV-negative compared with patients living with HIV. We could not determine whether the lower pCR rates led to reduced EFS and subsequent OS. In addition, other treatment factors, including differences in adherence to adjuvant endocrine therapy and adjuvant anti-HER2 therapy, could have contributed to lower OS. However, in the multivariable analysis where hormone receptor-positive status was forced into the model, the magnitude of the association between HIV-positive
and pCR was decreased suggesting that hormone receptor status may contribute partially to the lower pCR in our HIV-positive cohort. Our regression analysis within the limitations outlined suggests that RDI may be a contributor to lower pCR rates in the HIV-positive group in our cohort. Finally, among patients who are HIV-positive, CD4 and viral load data were missing for a substantial proportion of the patients. However, current Botswana treatment guidelines for HIV recommend the treat-all strategy, which aims to start anyone with a positive HIV diagnosis on treatment immediately, regardless of the CD4 count level. Subsequently, most patients who are HIV-positive have CD4 > 250 and are virally suppressed.

Despite these limitations, our study has several strengths. We analyzed detailed surgical pathology data and granular chemotherapy administration data and toxicity grading which informed our analyses. Our study showed lower RDI for patients who are HIV-positive and have breast cancer, especially those on ZDV ART, which is a novel finding and an important consideration for improving outcomes in patients who are HIV-positive receiving cytotoxic chemotherapy. Although ZDV-containing therapy is no longer first-line ART in Botswana, the median duration of ART for our population was 9.8 years, suggesting that at least half of the patients started therapy before updated guidelines which recommend dolutegravir as first-line therapy. Additionally, current guidelines do recommend certain ZDV-based therapies (eg, ZDV, lamivudine, and atazanavir coformulated with ritonavir) in the list of second-line therapies to be considered in patients living with HIV who develop specific resistant mutations on first-line therapy.

The OS disparity documented in our study is similar to those in large retrospective cohort analysis in the United States of patients who are HIV-positive and have breast cancer with increased all-cause mortality (HR = 4.62 [95% CI, 3.92 to 5.45]). Similar studies from SSA have shown lower OS in patients who are HIV-positive and have breast cancer compared with patients who are HIV-negative and have breast cancer. Notably, even among patients who are HIV-negative, although the 2-year OS for stage III patients was similar to rates in SSA, it was lower than 5-year OS for North American cohorts, which is 75%. The difference is likely related to lower rates of optimal therapy delivery, differences in general health care infrastructure between Botswana and North America, differences in disease biology and younger age at presentation. In addition, of note, 83% of our patient population had stage III disease, which is also higher than the proportion of patients with de novo breast cancer in a North American cohort (27% on the basis of 2012-2016 SEER data). This is likely reflective of lack of screening, breast cancer awareness, and early detection programs in Botswana, which is similar to most African countries.

We confirmed our hypothesis that pCR rates will be lower in patients who are HIV-positive. Nietz et al showed similar findings in a South African cohort with patients who are HIV-positive less likely to achieve pCR (OR = 0.48; 95% CI, 0.27 to 0.86). A potential mechanism may be disparities in dose intensity between the two groups, which was significantly associated with pCR in the multivariable analyses. The small sample size and the differences in proportion of missing molecular status data do not allow us to conclusively account for the contributions of molecular status and RDI on pCR. Importantly, we noted that the proportion of patients receiving optimal dose intensity was low in patients who are HIV-positive and HIV-negative, which is concerning and an indicator of suboptimal therapy delivery at baseline for all patients with breast cancer regardless of HIV status. HIV-positive is further associated with even lower dose intensity of therapy represented by a larger proportion of patients receiving low dose intensity therapy and a significantly lower mean RDI. Assessment of RDI in patients with locally advanced disease in Rwanda showed that 61.9% of those with locally advanced disease receiving NACT had RDI ≥ 0.85, compared with 44% in our cohort. These data are robust and important for assessing optimal therapy delivery and explaining disparities in outcomes; however, few countries in SSA have these data because of lack of electronic medical record systems, paper-based record keeping, and other logistical challenges.

We report a significant difference in RDI between patients who are HIV-positive and have breast cancer and patients who are HIV-negative and have breast cancer, which may contribute to lower rates of pCR and worse OS. We hypothesize that this could be partly due to toxicity in patients who are HIV-positive. In fact, although patients who are HIV-positive received significantly less dose intense therapy, toxicity rates were similar between the two groups, which suggests that patients who are HIV-positive were dose reduced in an attempt to prevent greater toxicity, although we do not have data on decision making by the providers to support that. Lower RDI may also be due to intolerance of the complete regimen among patients who are HIV-positive, evidenced by the higher but nonsignificant rate of premature treatment discontinuation in that group. Furthermore, our analysis suggests that differences in RDI may have been due to longer cycle lengths and time to treatment completion among patients who are HIV-positive compared with patients who are HIV-negative, which may also have been related to slower recovery after each cycle by patients who are HIV-positive. Furthermore, patients who are HIV-positive had more cycles with dose reductions compared with patients who are HIV-negative, which may be appropriate but also reflect a provider bias to recommend dose reduction or premature discontinuation of therapy in patients who are HIV-positive and experience toxicity compared with patients who are HIV-negative. The combined effects of higher premature discontinuation, dose reductions, and increased median duration of treatment cycle may contribute to lower RDI in patients living with HIV and in particular patients on ZDV. Since the design of the study, new National Comprehensive Cancer
Network guidelines states that ZDV is contraindicated in patients who are HIV-positive initiating cytotoxic chemotherapy because of risk of causing or exacerbating myelosuppression.\(^\text{31}\)

In conclusion, patients who are HIV-positive and have breast cancer have lower pCR rates, which may be due in part due to reduced RDI and may subsequently lead to worse OS. The frequency and magnitude of low dose intensity therapy among patients who are HIV-positive and have breast cancer highlight the challenges clinicians face in delivering optimal dose intensity treatment to this population. Although some risk factors are not modifiable, it is critical to examine implementation strategies that can specifically target modifiable risk factors associated with suboptimal therapy delivery for patients who are HIV-positive. Our next steps are to implement strategies for deimplementation of ZDV, whereby it is replaced with a safer alternative ART before initiation of cytotoxic chemotherapy. Additional considerations are the implementation of granulocyte colony-stimulating factor prophylaxis in patients living with HIV initiating AC-T or other cytotoxic chemotherapy regimens with high (≥20%) risk of myelosuppression. Our results highlight that these implementation strategies should be performed within a broader context of optimizing care delivery for all patients, including HIV-negative. These will include efforts to decentralize cancer care and increase breast cancer treatment access in Botswana and to improve standardization of chemotherapy administration and delivery of optimal dose intensity.

**AFFILIATIONS**

1Department of Medicine (Hematology-Oncology), University of Pennsylvania, Philadelphia, PA
2Botswana University of Pennsylvania Partnership, Gaborone, Botswana
3Department of Pathology, University of Pennsylvania, Philadelphia, PA
4Princess Marina Hospital, Gaborone, Botswana
5Gaborone Private Hospital, Gaborone, Botswana
6University of Pennsylvania, Department of Medicine (Infectious Diseases), Philadelphia, PA
7Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA

**CORRESPONDING AUTHOR**

Yehoda M. Martei, MD, MSCE, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104; e-mail: yehoda.martei@pennmedicine.upenn.edu.

**EQUAL CONTRIBUTION**

S.G. and A.D. equally contributed to this work.

**SUPPORT**

Y.M.M.’s research work is supported by an NIH K01 Award—K01TW011481, P30 AI 045008 NIH, Penn Center for AIDS Research Pilot Award.

**DATA SHARING STATEMENT**

Data are available upon reasonable request and will require local IRB approval or exemption in Botswana.

**AUTHOR CONTRIBUTIONS**

Conception and design: Yehoda M. Martei, Mohan Narasimhamurthy, Dipho I. Setlhako, Tlotlo Ralefala, Sebathu Chiyapo, Robert Gross, Lawrence N. Shulman, Surbhi Grover, Angela DeMichele

Financial support: Yehoda M. Martei, Lawrence N. Shulman, Surbhi Grover

Administrative support: Yehoda M. Martei, Lawrence N. Shulman, Surbhi Grover

 provision of study materials or patients: Dipho I. Setlhako, Gezahen Ayane

Collection and assembly of data: Yehoda M. Martei, Mohan Narasimhamurthy, Gezahen Ayane, Sebathu Chiyapo, Surbhi Grover, Angela DeMichele

Data analysis and interpretation: Yehoda M. Martei, Mohan Narasimhamurthy, Gezahen Ayane, Sebathu Chiyapo, Robert Gross, Lawrence N. Shulman, Surbhi Grover, Angela DeMichele

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/go/authors/author-center](http://ascopubs.org/go/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians [Open Payments](http://openpaymentsdata.cms.gov). The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/go/authors/author-center](http://ascopubs.org/go/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Robert Gross
Consulting or Advisory Role: Pfizer
Research Funding: Merck (Inst)

Lawrence N. Shulman
Research Funding: Celgene (Inst), Independence Blue Cross (Inst)

Surbhi Grover
Honoria: Varian Medical Systems
Consulting or Advisory Role: GenesisCare
Research Funding: Varian Medical Systems

Angela DeMichele
Research Funding: Pfizer (Inst), Genentech (Inst), Calithera Biosciences (Inst), Novartis (Inst)

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We wish to thank the following research personnel from their contributions: Lebogang Mokokwe, Goitsemang Gabaathole, Lame Bakwenabatsile, and Barati Monare.
REFERENCES

1. Trickey A, May MT, Vehreschild JJ, et al: Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV 4:e349-e356, 2017
2. McCormack VA, Feltwey-Combes O, Ginsburg O, et al: Breast cancer in women living with HIV: A first global estimate. Int J Cancer 143:2732-2740, 2018
3. Coghlin AE, Shields MS, Suneja G, et al: Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33:2376-2383, 2015
4. Coghlin AE, Pfeiffer RM, Shields MS, et al: Excess mortality among HIV-infected individuals with cancer in the United States. Cancer Epidemiol Biomarkers Prev 26:1027-1033, 2017
5. Brandão M, Bruzzone M, Franzoi MA, et al: Impact of HIV infection on baseline characteristics and survival of women with breast cancer. AIDS 35:605-618, 2021
6. Groser S, Martel YM, Puri P, et al: Breast cancer and HIV in sub-Saharan Africa: A complex relationship. J Glob Oncol 4:1-11, 2018
7. HIV and AIDS in Botswana. Avert. https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/botswana
8. Cancer today. https://gco.iarc.fr/today/fact-sheets-populations
9. Bhathia RK, Narasimhamurthy M, Martel YM, et al: Report of clinico-pathological features of breast cancer in HIV-infected and uninfected women in Botswana. Infect Agent Cancer 14:28, 2019
10. Cortazar P, Zhang L, Untch M, et al: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res 26:2839-2848, 2020
11. Spring LM, Fell G, Arfe A, et al: Pathologic complete response after neoadjuvant chemotherapy compared with histologic complete response. J Natl Compr Canc Netw 14:1128-1136, 2016
12. Zhang L, Yu Q, Wu XC, et al: Impact of chemotherapy relative dose intensity on cancer-specific survival in patients with stage II-IV breast cancer: A meta-analysis. J Cancer Res Clin Oncol 43:1113-1121, 2017
13. Chirivel A, Bermejo B, Insa A, et al: Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479-484, 2009
14. Lyman GH: Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7:99-108, 2009
15. Makhema J, Wirth KE, Pretorius Holme M, et al: Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med 381:175-187, 2018
16. NCCN: NCCN Framework for Resource Stratification of NCCN Guidelines -Invasive Breast Cancer, Enhanced Resources, version 2.2017. http://www.nccn.org/guidelines/publications/invasivebreastcancer-v2-2017.pdf
17. Common Terminology Criteria for Adverse Events (CTCAE)/Protocol Development. CTEP. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
18. DeSantis CE, Ma J, Goding Sauer A, et al: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67:439-448, 2017
19. Brogan KL, Zell SC. Hematologic toxicity of zidovudine in HIV-infected patients. Am J Hematol 41:1521-1528, 1990
20. Makwana S, Wirth KE, Pretorius Holme M, et al: Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med 381:230-242, 2019
21. Cohen MS, Chen YQ, Mc Caulley M, et al: Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 375:830-839, 2016
22. Handbook of the Botswana 2016 HIV integrated HIV clinical care guidelines. https://www.moh.gov.bw/Publications/Handbook_HIV_treatment_guidelines.pdf
23. McCormack V, McKenzie F, Foerster M, et al: Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): A prospective cohort study. Lancet Glob Health 8:e1203, 2020
24. DeSantis CE, Ma J, Gaudet MM, et al: Breast cancer statistics, 2019. CA Cancer J Clin 69:438-451, 2019
25. Mbuka-Ongona D, Tumbo JM: Knowledge about breast cancer and reasons for late presentation by cancer patients seen at Princess Marina Hospital, Gaborone, Botswana. Afr J Prim Health Care Fam Med 5:465, 2013
26. Chau CA, Huang L, Visvanathan K, et al: Understanding women’s perspectives on breast cancer is essential for cancer control: Knowledge, risk awareness, and care-seeking in Mwanza, Tanzania. BMC Public Health 20:930, 2020
27. Sharp JW, Hippe DS, Nakigudde G, et al: Modifiable patient-related barriers and their association with breast cancer detection practices among Ugandan women without a diagnosis of breast cancer. PLoS One 14:e0217938, 2019
28. Nietz S, O’Neil DS, Ayeni O, et al: A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection. Breast Cancer Res Treat 184:861-872, 2020
29. O’Neil DS, Keating NL, Dusengimana JMV, et al: Quality of breast cancer treatment at a rural cancer center in Rwanda. J Glob Oncol 4:1-11, 2018
30. Suneja G, Shiels MS, Melville SK, et al: Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 27:459-468, 2013
31. Specific populations. https://www.nccn.org/guidelines/category_4